For more details, please click [Read Original] below.
The content of this article is reprinted fromCore MedicalOfficial Account
Hetao Venture Capital was reorganized and established in 2014 under the strategic background of Tsinghua University’s promotion of technology transfer. It is a professional investment management institution primarily focused on early-stage investments in science and technology innovation enterprises. Hetao Venture Capital concentrates on key areas such as life sciences, medical devices, information technology, and modern manufacturing. It has long been dedicated to investing in innovative enterprises with core hard technologies, while also specializing in incubating technology achievements from universities and top hospital clinical experts. Currently, Hetao Venture Capital manages nearly 4 billion yuan in funds, with nearly 90 accumulated investment projects. It supports the commercialization of significant research discoveries and technological innovations made by scientists and entrepreneurs, achieving "commercial transformation from 0 to 1." At the same time, it consistently selects high-barrier "first-of-its-kind technologies" for early-stage investment. With outstanding performance, Hetao Venture Capital has received honors such as “Top 50 Early-Stage Investment Institutions in China” by The Financing and “Top 50 Best Early-Stage Venture Capital Institutions in China” by ChinaVenture.
